Tokyo Tape
Sign in
← Kaken Pharmaceutical

Quarterly report · Q2

4521.TEDINET S100PKU1
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥36.8bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥76.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥37.6bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥8.2bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥9.0bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥8.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥17.5bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥9.3bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥8.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥9.4bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥9.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.7bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥6.7bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥167.3bnat 2022-09-30Cons.Assets
Total assets¥165.2bnat 2022-03-31Cons.Assets
Total assets¥165.6bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥26.9bnat 2022-09-30Cons.Liabilities
Total liabilities¥26.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥140.4bnat 2022-09-30Cons.Net assets
Net assets / equity¥138.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥138.3bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥60.8bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥61.0bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥75.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.6bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥76.3bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥77.3bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥13.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥7.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.2bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥4.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥8.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥158.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥81.452022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥251.432021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥176.242021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥88.452021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio83.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio83.4%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio83.5%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥7.6bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2022-04-01 → 2022-09-30¥616m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥8.2bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2021-04-01 → 2021-09-30¥36.4bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2021-04-01 → 2021-09-30¥36.4bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2021-04-01 → 2021-09-30¥8.4bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2021-04-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2021-04-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2021-04-01 → 2021-09-30¥635m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥37.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥37.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥9.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 464
ItemContextValueUnit
Dividends income noiPrior1YTDDuration214000000JPY
Dividends income noiCurrentYTDDuration233000000JPY
Subsidy income noiPrior1YTDDuration－JPY
Subsidy income noiCurrentYTDDuration76000000JPY
Other noiPrior1YTDDuration60000000JPY
Other noiCurrentYTDDuration45000000JPY
Non operating incomePrior1YTDDuration278000000JPY
Non operating incomeCurrentYTDDuration358000000JPY
Interest expenses noePrior1YTDDuration8000000JPY
Interest expenses noeCurrentYTDDuration8000000JPY
Foreign exchange losses noePrior1YTDDuration6000000JPY
Foreign exchange losses noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration9000000JPY
Other noeCurrentYTDDuration3000000JPY
Non operating expensesPrior1YTDDuration23000000JPY
Non operating expensesCurrentYTDDuration12000000JPY
Ordinary incomePrior1YTDDuration9290000000JPY
Ordinary incomeCurrentYTDDuration8555000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration195000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration2000000JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration1000000JPY
Extraordinary incomePrior1YTDDuration195000000JPY
Extraordinary incomeCurrentYTDDuration4000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration49000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration25000000JPY
Impairment loss elPrior1YTDDuration－JPY
Impairment loss elCurrentYTDDuration304000000JPY
Extraordinary lossPrior1YTDDuration49000000JPY
Extraordinary lossCurrentYTDDuration330000000JPY
Income before income taxesPrior1YTDDuration9436000000JPY
Income before income taxesCurrentYTDDuration8229000000JPY
Income taxesPrior1YTDDuration2714000000JPY
Income taxesCurrentYTDDuration2265000000JPY
Profit lossPrior1YTDDuration6721000000JPY
Profit lossCurrentYTDDuration5964000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration－JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration－JPY
Profit loss attributable to owners of parentPrior1YTDDuration6721000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration5964000000JPY
Profit lossPrior1YTDDuration6721000000JPY
Profit lossCurrentYTDDuration5964000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration545000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration213000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration39000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration31000000JPY
Other comprehensive incomePrior1YTDDuration585000000JPY
Other comprehensive incomeCurrentYTDDuration245000000JPY
Comprehensive incomePrior1YTDDuration7306000000JPY
Comprehensive incomeCurrentYTDDuration6209000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass